Bio

My name is Andre Vu, and I am currently an MS1 at Stanford School of Medicine. Growing up in Little Saigon as a child of Vietnamese refugees, I have always felt deeply connected to my cultural heritage and community. This background has fueled my passion for addressing health disparities, particularly in underserved populations.

My interests lie in improving health disparities and fostering innovation within the healthcare sector. I believe that finding creative solutions and equitable resource distribution are crucial for improving health outcomes in marginalized communities. Outside of my academic and professional pursuits, I have a deep love for cooking Vietnamese cuisine. It is a way for me to stay connected to my roots and share my culture with others. I also enjoy expressing my creativity through painting and sculpting, which provide a wonderful balance to my studies and allow me to unwind.

I am committed to using my medical education to meaningfully impact healthcare accessibility and quality, and I am excited to be part of a future where every individual has the opportunity to achieve optimal health.

Contact

  • Academic
    andrevu@stanford.edu
    University - Student Department: School of Medicine Position: Graduate, Medicine

Additional Info

All Publications

  • Long-Term Outcomes for Patients Undergoing Hybrid Ablation for Atrial Fibrillation. The Journal of thoracic and cardiovascular surgery Weininger, G., Aparicio-Valenzuela, J., Yau, T., Vu, A., Pong, T., Lee, A. M. 2025

    Abstract

    Hybrid ablation (HA) for atrial fibrillation (AF) consists of a thoracoscopic epicardial ablation followed by an endocardial, catheter ablation. Several small randomized controlled trials have recently demonstrated the efficacy of this approach; however the data is limited by modest sample sizes with limited follow up. In this study we evaluate the long-term efficacy of HA in a large single-institution series over a ten-year period.Patients with refractory AF underwent HA between the years of 2015 and 2025 at a single institution with a single surgeon. Epicardial ablation consisted of pulmonary vein isolation, isolation of the posterior left atrium, and left atrial appendage clip application. Patient medical records were reviewed for demographics, comorbidities, medications, recurrence of AF, operative reports, pathology reports, length of hospital stay, stroke, and death. Recurrence was defined as AF > 30 seconds in duration beyond a 90-day blanking period on 24 hour or longer continuous monitoring. Patients were followed for up to nine years.304 patients were identified who underwent the first stage epicardial ablation, 239 of whom also completed the second stage endocardial ablation between the years of 2015 and 2025. At one year, 81% of patients were in normal sinus rhythm (NSR) and 64% were also off all class I and class III anti-arrhythmic drugs (AADs). At five years these rates were 66% and 47% respectively. 8 patients (2.6%) required conversion to open Maze and 30-day mortality occurred in 1 patient (0.3%). In 199 patients (65% of cases) the epicardial ablation was performed through a left sided only thoracoscopic approach, which was associated with a mildly shorter hospital length of stay compared to bilateral thoracoscopic approach (3 days vs 4 days, p=0.0038), lower rate of ICU admission (9% vs 18% p=.038), and equivalent rates conversion to open Maze and AF recurrence at 1 year. 14 patients were incidentally found to have amyloid deposits in left atrial appendage specimens sent for pathology, 3 of these patients had transthyretin (ATTR) subtype.In this large single-institution study of hybrid ablation outcomes over a 10-year period, we demonstrate excellent short and long-term freedom from AF with low rates of complication and conversion to open surgery. Left sided, unilateral thoracoscopic access was safe and benefitted patients' length of stay and rate of ICU admission. It may be beneficial to routinely send left atrial appendage specimens at the time of epicardial ablation.

    View details for DOI 10.1016/j.jtcvs.2025.11.017

    View details for PubMedID 41314536

  • Growing Use, Evolving Risk: A Contemporary Profile of Heart-Liver Transplantation Berg, A., Krishnan, A., Heng, E., Hu, S., Mullis, D., Vargas, N., Vu, A., Garrison, A., Alnasir, D., Clark, D., Haeffele, C., Lui, G., Teuteberg, J., Woo, Y., Macarthur, J. LIPPINCOTT WILLIAMS & WILKINS. 2025

    View details for DOI 10.1161/circ.152.suppl_3.4367893

    View details for Web of Science ID 001613950900034

  • Donor Renal Function Should Inform Evaluation of Circulatory Death Heart Offers Berg, A., Krishnan, A., Heng, E., Mullis, D., Garrison, A., Vu, A., Alnasir, D., Teuteberg, J., Woo, Y., Macarthur, J. LIPPINCOTT WILLIAMS & WILKINS. 2025

    View details for DOI 10.1161/circ.152.suppl_3.4366285

    View details for Web of Science ID 001613917100040

https://orcid.org/0000-0002-1365-3444